Anthem Bioscienc

Is Anthem Bioscienc overvalued or undervalued?

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.<BR><BR>In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.

How has been the historical performance of Anthem Bioscienc?

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

Answer:<BR>The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

When is the next results date for Anthem Biosciences Ltd?

The next results date for Anthem Biosciences Ltd is February 5, 2026.

The next results date for Anthem Biosciences Ltd is scheduled for February 5, 2026.

Should I buy, sell or hold Anthem Biosciences Ltd?

Why is Anthem Biosciences Ltd falling/rising?

As of 17-Mar, Anthem Biosciences Ltd's stock price is declining at 640.00, down 0.46%, underperforming its sector. Contributing factors include poor recent financial results, decreased investor interest, and trading below key moving averages.

As of 17-Mar, Anthem Biosciences Ltd is experiencing a decline in its stock price, currently at 640.00, reflecting a change of -2.95 (-0.46%). The stock has underperformed its sector by -0.74% today, indicating a weaker performance compared to its peers. <BR><BR>Over the past week, the stock has decreased by 4.48%, while the benchmark Sensex has only fallen by 2.73%. This trend continues over the past month, with the stock down 7.64% compared to an 8.84% decline in the Sensex. Year-to-date, the stock has seen a smaller decline of 1.70%, while the Sensex has dropped by 10.74%. <BR><BR>Today's trading activity shows that the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically indicates a bearish trend. Furthermore, there has been a significant drop in investor participation, with delivery volume on March 16 falling by 97.53% compared to the 5-day average, suggesting a lack of interest from investors.<BR><BR>The company's recent financial results have also contributed to the stock's decline. Negative results reported for December 25 show a decrease in profit before tax by 24.2%, net sales down by 18.3%, and profit after tax down by 14.1% compared to the previous four-quarter average. Despite having a high return on equity (ROE) of 19.93% and healthy long-term growth in net sales and operating profit, the stock's valuation appears expensive with a price-to-book value of 12.6. <BR><BR>In summary, the combination of poor recent financial performance, declining investor interest, and trading below key moving averages are key factors contributing to the falling stock price of Anthem Biosciences Ltd.

Why is Anthem Biosciences Ltd falling/rising?

As of 18-Mar, Anthem Biosciences Ltd's stock price is rising at 645.55, but it has shown declines over the past week and month, with decreased investor participation. Despite current gains, the stock's long-term outlook may be affected by recent negative trends and lower confidence among investors.

As of 18-Mar, Anthem Biosciences Ltd's stock price is rising, currently at 645.55, reflecting an increase of 10.15 (1.6%). This rise can be attributed to its performance today, where it outperformed its sector by 1.33% and reached an intraday high of Rs 650, marking a 2.3% increase. <BR><BR>Despite this positive movement, the stock has shown a decline over the past week and month, with returns of -0.45% and -6.10%, respectively. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a longer-term downward trend. <BR><BR>Investor participation has also decreased, with delivery volume falling by 37.55% compared to the 5-day average, which may suggest a lack of confidence among investors. However, the company maintains a high management efficiency with a return on equity (ROE) of 19.93% and a low debt-to-equity ratio, which supports its long-term growth potential, as evidenced by a net sales growth rate of 29.80% and an operating profit growth of 44.32%. <BR><BR>In summary, while the stock is currently rising, it faces challenges from recent negative financial results and declining investor participation, which could impact its future performance.

Why is Anthem Biosciences Ltd falling/rising?

As of 19-Mar, Anthem Biosciences Ltd's stock price is at 633.15, down 2.32%, reflecting a bearish trend in the pharmaceuticals sector. Decreased investor participation and negative financial results have contributed to the stock's decline, despite some long-term growth potential.

As of 19-Mar, Anthem Biosciences Ltd's stock price is falling, currently at 633.15, reflecting a decrease of 15.05 or 2.32%. This decline is consistent with the overall performance of the pharmaceuticals and drugs sector, which has fallen by 2.11%. The stock has also been trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>Investor participation has notably decreased, with delivery volume dropping by 72.64% compared to the 5-day average, suggesting reduced interest from investors. Additionally, the stock's performance over the past month shows a decline of 8.95%, which is better than the Sensex's drop of 10.05%, but still indicates weakness.<BR><BR>The company's recent financial results have contributed to the negative sentiment. In the latest quarter, the profit before tax (PBT) fell by 24.2% compared to the previous four-quarter average, and the profit after tax (PAT) decreased by 14.1%. Furthermore, net sales were reported at their lowest level of Rs 423.15 crore, which has raised concerns about the company's short-term performance.<BR><BR>Despite some positive factors, such as high management efficiency and healthy long-term growth rates, the recent negative financial results and declining investor interest have led to the stock's current downward trajectory.

Why is Anthem Biosciences Ltd falling/rising?

As of 20-Mar, Anthem Biosciences Ltd's stock price is rising to 645.90, reflecting a 2.01% increase. The stock has shown strong fundamentals and growth potential, attracting investor confidence despite recent negative financial results.

As of 20-Mar, Anthem Biosciences Ltd's stock price is rising, currently at 645.90, reflecting an increase of 12.75 or 2.01%. This upward movement is notable as the stock has outperformed its sector by 0.31% today and reached an intraday high of Rs 650, which is a 2.66% increase. Additionally, the stock has shown a positive performance over the past week, gaining 0.94% while the benchmark Sensex has slightly declined by 0.04%.<BR><BR>Despite a recent decline in delivery volume, which fell by 16.32% against the 5-day average, the stock remains liquid enough for trading. The company's strong fundamentals, including a high return on equity (ROE) of 19.93% and a low debt-to-equity ratio, contribute to investor confidence. Furthermore, Anthem Biosciences has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 29.80% and operating profit growing at 44.32%.<BR><BR>However, it is important to note that the company has faced challenges, including negative results reported for December 25, where profit before tax, net sales, and profit after tax all fell compared to previous quarters. Despite these setbacks, the stock's current rise can be attributed to its strong management efficiency and growth potential, which may be attracting investors despite the recent negative financial results.

Why is Anthem Biosciences Ltd falling/rising?

As of 23-Mar, Anthem Biosciences Ltd's stock price is at 625.05, reflecting a decline of 3.23%. The stock is underperforming with a negative return of 10.18% over the past month, influenced by disappointing financial results and high valuation metrics.

As of 23-Mar, Anthem Biosciences Ltd's stock price is falling, currently at 625.05, which reflects a decrease of 20.85 or 3.23%. This decline is evident as the stock opened with a loss of 2.39% today and reached an intraday low of Rs 625, marking a drop of 3.24%. The stock is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>In terms of performance relative to the market, the stock has outperformed its sector by 0.34%, but it has still experienced a negative return of 10.18% over the past month, compared to a 12.72% decline in the Sensex. The year-to-date performance shows a decrease of 3.99%, while the sector has fallen by 14.70%.<BR><BR>The recent financial results have contributed to the stock's decline, with negative outcomes reported for December 25, including a 24.2% drop in profit before tax and a 14.1% decrease in profit after tax compared to the previous four-quarter average. Additionally, net sales were reported at Rs 423.15 crore, the lowest in recent quarters. Despite the company's high management efficiency and healthy long-term growth rates, these negative financial results and the stock's expensive valuation, indicated by a price-to-book value of 12.3, have likely influenced investor sentiment negatively, leading to the current decline in stock price.

Why is Anthem Biosciences Ltd falling/rising?

As of 24-Mar, Anthem Biosciences Ltd's stock price is rising to Rs 647.00, up 2.94%, driven by strong relative performance, increased investor participation, and solid fundamentals despite some recent negative results. The company's long-term growth prospects remain positive, with significant annual growth in net sales and operating profit.

As of 24-Mar, Anthem Biosciences Ltd's stock price is rising, currently at Rs 647.00, reflecting an increase of Rs 18.45 or 2.94%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.82% today, indicating strong relative performance. Additionally, it reached an intraday high of Rs 647, which aligns with the positive momentum observed in the market.<BR><BR>Investor participation has also significantly increased, with a delivery volume of 18.21 lacs on 23 March, which is a remarkable rise of 2051.84% compared to the 5-day average. This surge in trading activity suggests heightened interest and confidence among investors. Furthermore, the company exhibits strong fundamentals, including a high return on equity (ROE) of 19.93% and a low debt-to-equity ratio, which enhances its financial stability.<BR><BR>Despite some negative results reported in December, such as a decline in profit after tax and net sales, the overall long-term growth prospects remain healthy, with net sales growing at an annual rate of 29.80% and operating profit at 44.32%. These factors contribute to the stock's current upward trajectory, reflecting a combination of strong performance metrics and increased investor engagement.

Why is Anthem Biosciences Ltd falling/rising?

As of 25-Mar, Anthem Biosciences Ltd's stock price is rising at 645.90, but it faces challenges from recent negative financial results and declining investor participation, which may affect future performance. Despite a recent gain, the stock has underperformed its sector and shows volatility over the past month.

As of 25-Mar, Anthem Biosciences Ltd's stock price is rising, currently at 645.90, with a change of 5.55 (0.87%) upward. This increase follows a trend where the stock has gained for the last two days, resulting in a total return of 2.76% during this period. The stock also reached an intraday high of Rs 657.25, reflecting positive trading activity.<BR><BR>Despite this recent rise, the stock has underperformed its sector by 1.02% today and has shown a decline of 0.35% over the past week. Year-to-date, the stock has decreased by 0.79%, which is relatively better compared to the Sensex's decline of 11.67%. However, the stock's performance over the past month shows a more significant drop of 8.20%, indicating some volatility.<BR><BR>Investor participation appears to be declining, as evidenced by a 5.31% decrease in delivery volume compared to the five-day average. Nevertheless, the stock remains liquid enough for trading, with a value of Rs 0.74 crore based on 2% of the five-day average traded value.<BR><BR>On a positive note, the company demonstrates high management efficiency with a return on equity (ROE) of 19.93% and a low debt-to-equity ratio, which suggests financial stability. Additionally, the company has shown healthy long-term growth, with net sales increasing at an annual rate of 29.80% and operating profit at 44.32%. <BR><BR>However, there are concerns due to negative quarterly results reported for December 25, where profit after tax (PAT) fell by 14.1% compared to the previous four-quarter average, and net sales were at their lowest. This has contributed to a perception of the stock being overvalued, with a price-to-book value of 12.7.<BR><BR>In summary, while Anthem Biosciences Ltd is currently experiencing a rise in stock price, it faces challenges from recent negative financial results and declining investor participation, which could impact its future performance.

Which are the latest news on Anthem Bioscienc?